21:19

# Index

Accredited investors, angel finance and, 75 ACE (allowance for corporate equity), 528-529, 542-544 Acquisitions. See Mergers and acquisitions Active prospecting, 13, 14 Acumen Fund, 144 Advanced-HR's OptionImpact database, life cycle and VC staging, 249, 252–253 Advising. See Monitoring and advising Agency problem: Canadian public venture capital market, 506-508 conflicts of interest, 367, 373 exits, 399-401 Alantec Inc., 378, 380-381 Allocation of control, opportunism and, 354-355, 356 Allowance for corporate equity (ACE) 528-529, 542-544 Altercentric uncertainty, 226-228 American Research and Development (ARD), 278, 557, 560 Angel finance, 71–110, 300 background, 75 conflicts of interest, 358 contrasted to VC, 106 control, 82-83, 104-106 sample description, 76-106 size of market, 71-72 theoretical findings, 73-75 Angel finance, externalities and moral hazard, 191-219 empirical implications, 207-211 model, 194-198 outcomes with financial constraints, 200-202 outcomes without financial constraints, 202-204 VC investment contrasted, 205-206, 211-216 Antecedents, of syndication decision, 222-228, 236-237

need and opportunity interplay, 226-228 role of investment strategy and PFC characteristics, 223-226 Anti-dilution measures, 371-372 Antitakeover protections (ATPs), 64–65 Arthur Andersen LLP, 325 Assets, due diligence and, 20 Asset tunneling, 367, 374 Asymmetric information issues. See also Conflicts of interest bank versus VC financing, 36–38 Canadian public venture capital market, 502, 505-508 CVC financing, 63 exits, 399, 400-401 innovation, 307 public policy, 561-563 Attention/interpretation/action. See Decision making Auditors, VC reputation and, 324–325 Australia, 557, 566 Bank financing, 31-50, 300 asymmetric information issues, 36-38 future research, 47 incomplete contracting issues, 38-47 moral hazard issues, 33-36 public policy and taxation, 529-533, 544-545 SMEs, 112 VC reputation, 325-326 Benchmarking, negotiation and decision making, 22-23 Biases, decision making and, 15-16, 20, 23 Blendermann, Gene, 379, 380 Boards of directors: angel finance, 72, 82, 83-85 contract terms, 23-24 CVC financing, 65-66 reputation, 334, 338 syndication, 229-230 Brick-and-mortar (BAM) incubators, 117

# Index

21:19

Business development, business incubator process and, 118, 119 Business incubation, 111-129 concept and history overview, 113-117 future research, 127-128 international aspects, 114, 120-123, 124 operational overview, 117-120 process, 118-120 SMEs, 111-113 success determinants, 120 types of, 114-117 venture capital, 123, 125–127 Business plan, business incubators and, 119 Buy-back provisions, exits and, 391 Cahen-Salvador, Gilles, 143 Call and put options, contracts and exits, 391 CalPERS/CalSTRS, 138 Canadian public venture capital market, 501-523 Canadian stock market and, 502-505 entrance mechanisms, 508-513 performance measurement, 513-515 returns, 518-519 successes and failures, 504-508, 515-518 Capital gains tax, 527, 528, 536, 538-539 Capital pool company (CPC), Canada, 503 506, 509-513 Carried interest, 424 Cash flow: conflicts of interest, 370 monitoring and advising, 169–186 value-added, 155-156, 286-289 Cash flow taxes, 542–544 CEO replacement, VC opportunism and, 347, 355, 357 Collusion prevention, monitoring and advising, 169-186 Commercial banks, VC reputation and, 325-326 Committed and drawn down funds, returns and, 432-433 Compensation. See also Return on investment conflicts of interest, 370 maturation dynamics, 266-269 reputation, 334 Competition, returns and, 429 Complementarity of effort, bank versus VC financing, 38–42 Conflicts of interest, 365-385 angel investors, 368 contractual solutions to, 369-375 entrepreneurs, 367-368

exit counterparties, 367-369 investors, 366-367 litigation case studies, 378-382 policy implications, 382-383 reputation, 375-378 syndicates, 366, 368 Contracts. See also Opportunism angel finance, 72, 82, 87-89 conflict of interest solutions, 369-375 contract terms and decision making, 23 - 24exits, 390-392 incomplete contracting issues, bank versus VC financing, 38-47 monitoring and advising, 169-186 reputation, 334-335 Contracts, value-added and, 153-167 empirical predictions, 162-163 forms of value-added, 153-155 literature review, 286–292 model of start-up financing, 157 moral hazard, 158–161, 164–166 Control rights. See also Control rights, relationship to performance; Opportunism angel finance, 82–83, 104–106 conflicts of interest, 372-373 exits, 390-392 future research, 467 monitoring and advising, 169-186 value-added and contracts, 155-156 value-added literature review, 286-289 Control rights, relationship to performance, 439-469 data, 442-443, 444-445 methodology of study, 441-442 results, 443, 446-456 robustness tests, 456-466 styles of control, 440-441 Convertible securities. See also Equities bank versus VC financing, 31 conflicts of interest, 370 exits, 390-392 opportunism, 348-349 value-added and contracts, 155-156 value-added literature review, 289-290 Cooper, Stanley, 379–380 Cooper v Parsky, 378, 379–380 Corporate incubators, 116–117 Corporate law, as solution to opportunism, 353-354 Corporate policies, maturation dynamics, 261, 263-265 Corporate taxes, 538

#### INDEX

Corporate venture capital (CVC), 51-70, 300 about, 51-52 advantages and disadvantages to portfolio firms, 55-61 future research, 66 governance, 62-66 strategic benefits to parent corporation, 52 - 55Cost of capital, public policy and subsidies to, 536, 540, 541-542 Creditor contracts, 375 Cross-border venture capital and private equity, 473-499 fundraising, 476, 488 future research, 495-496 general partners, 493-494 implications for stake holders, 492-495 research on, 475-492 underpinnings of study, 492-493 value adding, 488-492 CVC. See Corporate venture capital Dawson, Stephen, 142 Deal flow (origination), 11-14 future research, 13-14 Decision making, 9-30. See also Due diligence deal flow, 11-14 information processing theory, 10-11 negotiation, 22-25 screening, 14-19 Delisting, Canadian public venture capital market, 502, 513-514. See also Failure rates **DELOC**, 123 Demand right, contracts and exits, 391 Demographics, decision making and, 17 Denmark, 567 Dilution, exits and, 400 Diversification, agency conflicts and exits, 399 Dividend tax, 528, 538-539 Double-sided moral hazard, 33-36 Dow Jones-Venture One, 377 Drag-along right, contracts and exits, 391, 392 Due diligence, 19-22 business incubator process, 162-163 Canadian public venture capital market, 505-506 of entrepreneurs, 382 future research, 21-22 philanthropic venture capital, 143, 144 value-added and contracts, 154 Dynamics, of syndication, 229-231, 237

ECON IT, 123 Egocentric uncertainty, 226-227 Emerging markets, business incubators and, 114 Employee benefits, maturation dynamics, 265-266 Employee number and composition, maturation dynamics, 256-258 Employment terms, conflicts of interest and, 373 Entrepreneurs. See also Founders; Portfolio company (PFC) conflicts of interest, 367-368, 370-371, 373-374, 376 cross-border ventures, 493 due diligence, 382 entrepreneur/investor input complementarity, 38-42 Equities. See also Convertible securities; IPO; SEO maturation dynamics, 264, 265, 269–270 reputation, 321-327 Europe: business incubation, 121, 122-123, 124 data collection, 473 exits, 393 philanthropic venture capital, 138–140, 142 - 143returns, 430 VC rates, 525 European Business Network (EBN), 122-123 European Private Equity & Venture Capital Association (EVCA), 425, 433, 525-526 European Venture Philanthropy association (EVPA), 142 Exits, 389-405. See also IPO; SEO about, 389-390 agency conflicts, 399-400 business incubator process, 118, 119-120 common problems, 400-401 conflicts of interest, 367-369 contracts and control rights, 390-392 cross-border ventures, 492 future research, 401-402 nonrandomness of and study of control styles, 456-459 opportunism, 348, 358 philanthropic venture capital, 146-147 route types, 392-396 timing of, 396-398 value-added literature review, 292-294 Expropriation, bank versus VC financing, 37-38

587

# Index

21:19

Externalities, moral hazard and, 191-219 angel and VC investment compared, 211-216 angel investment, 198-204 empirical implications, 207-211 model, 194-198 VC investment, 205-206 Failure rates: reputation, 332-333 stigma of failure, and bank versus VC financing, 42-45 syndication, 234-236 Finland, 491, 560, 564, 569 First refusal rights: conflicts of interest, 371-372 exits, 391 Fore Systems, 380 Foundations. See Philanthropic venture capital Founders. See also Entrepreneurs employment terms and conflicts of interest, 373-374 maturation dynamics, 270, 271 France, 526, 567 Free-rider problem, 193 Freezeouts, avoiding, 373 Funding rounds, angel finance and, 92–95 96-97 Fund raising: conflicts of interest, 369-370 cross-border ventures, 188, 476 Future research: bank versus VC financing, 47 business incubation, 127-128 control styles and periormance, 467 corporate venture capital, 66 cross-border ventures, 495-496 deal flow, 13-14 due diligence, 21-22 exits, 401-402 negotiation, 24-25 philanthropic venture capital, 148 public policy, 577-578

reputation, 339–340 returns, 433–434 screening, 18–19 syndication, 237–238

General partners, cross-border ventures, 493–494 Geographic proximity, 281–282. *See also* Cross-border venture capital angel financing, 73, 103–104 innovation, 309–311 VC financing, 106, 278 Germany, 526, 567 Gore, Al, 138 Governance. *See also* Opportunism, governance and conflicts of interest, 372–373 contract terms and decision making, 23–24 CVC financing, 62–66 reputation, 329–331, 338

Herding phenomenon, 16Human capital potential, decision making and, 20Hybrid financing, 23, 566–567

ID-arbitration, 352 Impetus Trust, 142 Income taxes, 527 Incomplete contracting issues: complementarity of effort, 38-42 CVC imancing, 63 stigma of failure, 42–45 surategic uncertainty, 45–46 Incubation. See Business incubation India, 491 Industry distribution, 278, 280 innovation, 309-311 study of control styles, 457, 460 Information processing theory. See Decision making Initial consultation, business incubator process and, 118 Innovation, 299-317 data, 308-312 distorted strategy and exits, 400 imperfect contractibility of and exits, 399-400 innovation defined, 300-302 public policy and taxation, 526 statistics, 302-305 theoretical linkages with VC, 304-308 venture capital defined, 209-300 Intellectual property, innovation and, 307 Intermediaries, VC reputation and auditing, 324-325 commercial banks, 325-326 future research, 339-340 intermediation, 321-327 measuring of, 336-338 role of, 319-321 underwriting, 322-324

March 31, 2010

## INDEX

21:19

International funds. See Canadian public venture capital market; Cross-border venture capital and private equity International issues: business incubation, 114, 120-123, 124 context and screening, 18 enterprise centers, 115, 116, 117 philanthropic venture capital, 132-135 value-added and contracts, 164 Internet bubble, business incubators and VC, 125-126, 127 IPO (initial public offering): conflicts of interest, 366, 369 CVC financing, 62-65 as exit route, 392, 393-394 maturation dynamics, 252 opportunism, 358 penny stock process and Canadian public venture capital market, 508 reputation, 323-324, 328-331, 336-338 screening and monitoring, 286 value-added literature review, 293-294 Ireland, 564 Israel, 475, 564, 574

Kalashian, Michael, 380–381 Kalashian v. Advent, 378, 380–381 Knowledge-sharing perspective, of syndication, 224–226, 232–234

Later-round financing, opportunism and, 248, 357-358 Life cycle theory, maturation dynamics, 245-275 cash compensation, 266-269 corporate policies, 261, 263-265 employee benefits, 265-266 employee number and composition, 256-258 equity holdings, 264, 265 equity values and financing, 269-270 founders, 270, 271 literature review, 247-249 maturation dynamics, 254-270 organizational hierarchy, 258-260 propositions, 250-251 quasi-time series data, statistical analysis framework, and economic hypotheses, 250-254 quasi-time series dataset, 249-250 revenues, 255-256

Limited partners: conflicts of interest, 366–367, 369–370, 375 cross-border ventures, 494 reputation, 334 Liquidation: as exit route, 393 monitoring and advising, 169–186 Liquidity gap, SMEs and, 111–112 Liquidity risk, exits and, 401 Liquid stock markets, public policy and, 545–546 Litigation, over conflicts of interest, 378–382

Management buyout, as exit route, 393, 396 Management fees, returns and, 424 Market failures, public policy and, 561-563 Maturation dynamics, 245-275 cash compensation. ?66-269 corporate policies, 261, 263-265 databases, 250-253 employee benefits, 265-266 employee number and composition, 256-258 equity holdings, 264, 265 equity values and financing, 269–270 founders, 270, 271 literature review, 247–249 maturation dynamics, 254-270 organizational hierarchy, 258–260 propositions, 250-251 quasi-time series data, statistical analysis framework, and economic hypotheses, 9, 253-254 quasi-time series dataset, 249-250 revenues, 255-256 Mergers and acquisitions: Canadian public venture capital market, 514 as exit route, 393, 395-396 reputation and, 330 screening and monitoring, 286 Milestones, control and conflicts of interest, 372 Monitoring and advising, 169–189 advising, 180-181 Canadian public venture capital market, 506-508 model for, 171-174, 182-186 monitoring, 174-179 philanthropic venture capital, 143, 145–146 reputation, 337 value-added and contracts, 154-155 value-added literature review, 278-289

589

# Index

21:19

Moral hazard issues. See also Conflicts of interest angel finance, 72-73 bank versus VC financing, 33-36 innovation, 307 monitoring and advising, 169–186 value-added and contracts, 158-161, 164-166 Moral hazard issues, project externalities and, 191-219 angel and VC investment compared, 211-216 angel investment, 198-204 empirical implications, 207-211 model, 194-198 VC investment, 205-206 Negotiation, 22-25 future research, 24-25 philanthropic venture capital and, 143, 145 Netherlands, 526 Networked incubators, 115 New products, as measure of innovation, 301 Noncompete clauses, exits and, 391-392 Norm-based constraints, as solution to opportunism, 352-353 North America, business incubation in, 121,

122, 124

Opportunism, governance and, 347–363. See also Conflicts of interest allocation of control, 354-355, 356 CEO replacement, 347, 355, 357 corporate law, 353–354 exit, 348, 358 issues of, 347-348 later-round financing, 248, 357-358 renegotiation, 350-351 reputational/norm-based constraints, 352-353 shared control, 352 sources of conflict, 348-349 state-contingent control, 351 Organizational hierarchy, maturation dynamics, 258-260 Origination. See Deal flow Outcomes. See Performance outcomes Overconfidence, of VCs, 16-17 Patents, as measure of innovation, 301, 302, 310-311

Patient capital, innovation and, 306

Penny stock IPO process, Canadian public venture, 508 Performance outcomes: control styles, 443, 446-453 syndication, 231-236, 237-238 Perkins, Kleiner, 138 Petrowax PA Inc., 379-380 PFC. See Portfolio company Philanthropic venture capital, 131-150 about, 131-132 approaches to, 140-141 current grantmaking challenges, 132-135 definitions, 136-138 examples of successful, 142-143 future research, 148 key data, 138-140 social and commercial entrepreneurship contrasted, 135 VC contrasted, 143-147 Phi Trust Foundation, 143 Portfolio company (PFC), syndication and, 221-242. Sce also Entrepreneurs; antece tents, 222-228, 236-237 conceptual perspectives, 222 dynamics, 229-231, 237 need and opportunity interplay, 226–228 outcomes, 231–236, 237–238 role of investment strategy and PFC characteristics, 223-226 Preemptive rights, exits and, 391 Prize for Green Innovation, 138 Productivity growth, as measure of innovation, 301-302 Profit orientation, business incubator classification and, 114, 115 Public policy, 525-552 academics' potential contribution to, 553-557 bank financing, 529-533 cross-border ventures, 494-495 future research, 577-578 meditations on private/public cooperation and benefits, 557-578 subsidies to cost of capital, 536, 540, 541-542 tax policies, 525-529, 535-544 tax reform, 542-544 value-added, 533-535, 544-545

Refinancing, as exit route, 393, 396 Registration right, contracts and exits and, 391 Regulations, innovation and, 308

March 31, 2010

SEC Rule 501, 75

Selection process, philanthropic venture

### INDEX

21:19

Renegotiation, as solution to opportunism, 350-351 Repurchase, as exit route, 393, 396 Reputation, of PFCs, uncertainty and syndication, 227, 228, 231 Reputation, of VCs, 319–346 auditing, 324-325 commercial banks, 325-326 conflicts of interest, 375-378 exit timing, 397 future research, 339-340 importance of, 319-321 intermediation, 321-327 litigation, 381-382 measures and measuring of, 336-338, 377-378 opportunism, 352-353 underwriting, 322-324 Research and development (R&D), as measure of innovation, 301, 302 Research and technology parks, contrasted to business incubators, 113 Return on investment, 407-437, 520. See also Compensation Canadian public venture capital market, 518-519 difficulties analyzing, 432-433 future research, 433-434 influences on, 429-432 investee performance evidence, 428-429 philanthropic venture capital, 147 returns evidence, 425-427 structure of returns, 407, 424 studies of returns, 408-423 target rates, 424-425 Revenues, maturation dynamics, 255-256 Reverse causality, innovation and, 311-312 Reverse mergers, Canadian public venture capital market, 503, 508-509 Risk, decision making and, 19-21 Risk-sharing perspective, of syndication, 224-226 Roberts, George, 142 Roberts Enterprise Development Fund (REDF), 142, 144, 147 Rockefeller, John D. III, 136 Screening, 14–19. See also Due diligence business incubator process, 118, 119 future research, 18–19

#### future research, 18–19 value-added literature review, 278–289 Secondary sale, as exit route, 393, 396

capital and, 143, 144 SEO (seasoned equity offering), reputation and, 323-327 Shared control, as solution to opportunism, 351 Silicon Valley Bank, 375 Silicon Valley Community Foundation (SVCF), 142 Single-sided moral hazard, 35 Small and medium-sized enterprises (SMEs), business incubation and, 111-129 concept and history overview, 113-117 future research, 127-128 importance of and need for capital, 111-113 international aspects, 114, 120-123, 124 operational overview, 117–120 process of funding, 118-120 success determinants, 120 types of incubators, 114-117 venture capital and, 123, 125-127 Small Business Innovation Research (SBIR) program, 527–528 SMEs. See Small and medium-sized enterprises Social entrepreneurs. See Philanthropic venture capital Socially responsible investment (SRI), 131-132, 137 Social return on investment (SROI), 147 South Africa, 564, 569 Southwest Venture Partners II, 379-380 Staging. See also Maturation dynamics angel finance, 72, 82, 85-87 Canadian public venture capital market,

591

Canadian public venture capital market, 511, 513 conflicts of interest, 372–373

value-added, 286–292 State-contingent control, as solution to

opportunism, 351 Status of organization, uncertainty and syndication, 227–228

Stigma of failure, bank versus VC financing, 42–45

Stock options, public policy and, 545

Strategic uncertainty, bank versus VC

financing, 45–46

Strong, Kevin, 503

Success taxes, 528, 536, 537–539

Sweden, 526 Switzerland, 526

Syndication, 20-21, 22, 221-242

# Index

angel finance, 95, 97-103 antecedents, 222-228, 236-237 conceptual perspectives, 222 conflicts of interest, 366, 368, 376-377 cross-border ventures, 489, 490 dynamics, 229-231, 237 future research, 237-238 literature review, 286-292 need and opportunity interplay, 226-228 outcomes, 231-236, 237-238 returns, 431 role of investment strategy and PFC characteristics, 223-226 Tag-along right, contracts and exits and, 391 Tax policies, 525-552 about, 525-529 bank financing, 529-533 reform proposals, 542-544 subsidies to cost of capital, 528, 536, 540 success taxes, 536, 537-539 value-added, 533-535, 544-545 wage tax, 536-537 Technical expertise, innovation and, 307-308 Tenancy application submission, business incubator process and, 118-119 Termination, agency conflicts and exits, 399 TheFunded.com, 377-378, 382 Third generation incubators, 115, 116, 117 Third-party certification. See Intermediaries Thomson Financial–VentureXpert, 377 Time trends, in VC financing, 278, 279 Total factor productivity (TFP): innovation measurement, 301-303, 311 reputation, 332 value-added, 284-286 Trade sale, as exit route, 393, 395–396 Transaction costs, returns and, 424 TSX Venture Exchange (TSVX), Canada, 501-523 Canadian stock market and, 502-505 entrance mechanisms, 508-513 performance measurement, 513-515 returns, 518-519 successes and failures, 515-518 success questioned, 504-508 Underwriting, VC reputation and, 322-324

Uninformed investors, 173

United Kingdom, public policy, 526, 560, 562, 563, 567, 568–569, 570 United States, philanthropic venture capital, 138–140, 142. *See also* Public policy University incubators, 116 Unsolicited proposals, 12–13 U.S. Petroleum Corp. (USP), 379–380

Valuation, negotiation and decision making, 22-23 Value-added: cross-border ventures, 488-492 innovation, 306-307 philanthropic venture capital, 134-135, 143, 145–146 public policy and taxation, 533-535, 544-545 Value-added, financial contracts and, 153-167 contracts of, 155-157, 161-162 empirical predictions, 162-163 forms of, 153-155 model of start-up financing, 157 moral hazard, 158–161, 164–166 Value added, literature review, 277–298 contracting, staging, syndication, 286–292 exits, 292–294 screening and monitoring, 278-286 Venture capital firms (VCs): geographic locations of financing, 278, 281-282 history, 278 industry distribution in financing, 278, 280 time trends in financing, 278, 279 venture capital defined, 209-300 Venture capital for sustainability (VC4S), 131, 132, 138 VentureOne surveys, life cycle and VC staging, 249, 251-252 Vesting schedules, exits and, 391 Vij, Jagdish, 380-381 **VIPIA**, 123 Virtual incubators, 117 Wage tax, 536–537

Wakerly, John, 380 Warm referrals, 12–13, 14 Weber, Max, 565 Write-off, as exit route, 393 WSGP-International, Inc., 379